Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 14, 2017, Pages E2911-E2919

  Fabbri, Giulia ^a   Holmes, Antony B ^a   Viganotti, Mara ^a   Scuoppo, Claudio ^a   Belver, Laura ^a   Herranz, Daniel ^a   Yan, Xiao Jie ^b   Kieso, Yasmine ^b   Rossi, Davide ^c,d   Gaidano, Gianluca ^e   Chiorazzi, Nicholas ^b   Ferrando, Adolfo A ^a,f   Dalla Favera, Riccardo ^a,f  

^a Columbia University ^*  (United States)

^b Northwell Health   (United States)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^d INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^f Department of Medicine   (United States)

Author keywords

Chronic lymphocytic leukemia; NOTCH1; Transcriptional network

Indexed keywords

MYC PROTEIN; NOTCH1 RECEPTOR; NOTCH1 PROTEIN, HUMAN;

ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; REGULATORY SEQUENCE; TRANSACTIVATION; BLOOD; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; MUTATION; ONCOGENE MYC; PATHOLOGY; PHYSIOLOGY;

B-LYMPHOCYTES; CELL PROLIFERATION; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, MYC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; RECEPTOR, NOTCH1;

EID: 85016978871     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1702564114     Document Type: Article

References (84)

1. Fabbri G, Dalla-Favera R (2016) The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer 16(3):145-162.
2. Pekarsky Y, Zanesi N, Croce CM (2010) Molecular basis of CLL. Semin Cancer Biol 20(6): 370-376.
3. Fabbri G, et al. (2011) Analysis of the chronic lymphocytic leukemia coding genome: Role of NOTCH1 mutational activation. J Exp Med 208(7):1389-1401.
4. Puente XS, et al. (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475(7354):101-105.
5. Wang L, et al. (2011) SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 365(26):2497-2506.
6. Quesada V, et al. (2011) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44(1):47-52.
7. Puente XS, et al. (2015) Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526(7574):519-524.
8. Weng AP, et al. (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306(5694):269-271.
9. Belver L, Ferrando A (2016) The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer 16(8):494-507.
10. Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway: Unfolding the activation mechanism. Cell 137(2):216-233.
11. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S (2012) The Notch signalling system: Recent insights into the complexity of a conserved pathway. Nat Rev Genet 13(9):654-666.
12. Rossi D, et al. (2012) Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 119(2):521-529.
13. Fabbri G, et al. (2013) Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 210(11):2273-2288.
14. Balatti V, et al. (2012) NOTCH1 mutations in CLL associated with trisomy 12. Blood 119(2):329-331.
15. Stilgenbauer S, et al. (2014) Gene mutations and treatment outcome in chronic lymphocytic leukemia: Results from the CLL8 trial. Blood 123(21):3247-3254.
16. Pozzo F, et al. (2016) NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation. Leukemia 30(1):182-189.
17. Maura F, et al. (2015) Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia. PLoS One 10(3):e0118801.
18. Arruga F, et al. (2014) Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia 28(5):1060-1070.
19. Kluk MJ, et al. (2013) Gauging NOTCH1 activation in cancer using immunohistochemistry. PLoS One 8(6):e67306.
20. Onaindia A, et al. (2015) Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation. Haematologica 100(5):e200-e203.
21. Stein H, et al. (1980) Immunohistologic analysis of the organization of normal lymphoid tissue and non-Hodgkin's lymphomas. J Histochem Cytochem 28(8):746-760.
22. Rosati E, et al. (2009) Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 113(4):856-865.
23. Klein U, et al. (2003) Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci USA 100(5):2639-2644.
24. Klein U, et al. (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. JExpMed194(11):1625-1638.
25. Seifert M, et al. (2012) Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 209(12):2183-2198.
26. Kulis M, et al. (2012) Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 44(11):1236-1242.
27. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545-15550.
28. Andersson ER, Lendahl U (2014) Therapeutic modulation of Notch signalling-Are we there yet? Nat Rev Drug Discov 13(5):357-378.
29. Kawata A, et al. (1993) Establishment and characterization of the tumors of chronic lymphocytic leukemia cell line in nude and SCID mice. Leuk Res 17(10):883-894.
30. Meerbrey KL, et al. (2011) The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci USA 108(9):3665-3670.
31. Shlyueva D, Stampfel G, Stark A (2014) Transcriptional enhancers: From properties to genome-wide predictions. Nat Rev Genet 15(4):272-286.
32. Bernstein BE, et al. (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125(2):315-326.
33. Béguelin W, et al. (2013) EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23(5):677-692.
34. Pott S, Lieb JD (2015) What are super-enhancers? Nat Genet 47(1):8-12.
35. Whyte WA, et al. (2013) Master transcription factors and mediator establish superenhancers at key cell identity genes. Cell 153(2):307-319.
36. Lovén J, et al. (2013) Selective inhibition of tumor oncogenes by disruption of superenhancers. Cell 153(2):320-334.
37. Hnisz D, et al. (2013) Super-enhancers in the control of cell identity and disease. Cell 155(4):934-947.
38. Chapuy B, et al. (2013) Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24(6):777-790.
39. Ewen ME, et al. (1993) Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73(3):487-497.
40. Joshi I, et al. (2009) Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood 113(8):1689-1698.
41. Cimmino A, et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102(39):13944-13949.
42. De Falco F, et al. (2015) Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL. Oncotarget 6(18):16559-16572.
43. Roberts AW, et al. (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):311-322.
44. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132(3):344-362.
45. Cornall RJ, et al. (1998) Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 8(4):497-508.
46. Reth M, Brummer T (2004) Feedback regulation of lymphocyte signalling. Nat Rev Immunol 4(4):269-277.
47. Burger JA (2011) Nurture versus nature: The microenvironment in chronic lymphocytic leukemia. Hematology: ASH Education Program 2011(1):96-103.
48. Calissano C, et al. (2009) In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 114(23):4832-4842.
49. Rossi D, et al. (2011) The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 117(12):3391-3401.
50. Herranz D, et al. (2014) A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat Med 20(10):1130-1137.
51. Palomero T, et al. (2006) NOTCH1 directly regulates c-MYC and activates a feedforward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 103(48):18261-18266.
52. Ryan RJ, et al. (2015) Detection of enhancer-associated rearrangements reveals mechanisms of oncogene dysregulation in B-cell lymphoma. Cancer Discov 5(10):1058-1071.
53. Edelmann J, et al. (2012) High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 120(24):4783-4794.
54. Holmes R, Zuniga-Pflucker JC (2009) The OP9-DL1 system: Generation of T-lymphocytes from embryonic or hematopoietic stem cells in vitro. Cold Spring Harb Protoc 2009(2):pdb.prot5156.
55. O'Neil J, et al. (2007) FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 204(8):1813-1824.
56. Messmer BT, et al. (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115(3):755-764.
57. Gómez-del Arco P, et al. (2010) Alternative promoter usage at the Notch1 locus supports ligandindependent signaling in T cell development and leukemogenesis. Immunity 33(5):685-698.
58. Ashworth TD, et al. (2010) Deletion-based mechanisms of Notch1 activation in T-ALL: Key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood 116(25): 5455-5464.
59. Haydu JE, et al. (2012) An activating intragenic deletion in NOTCH1 in human T-ALL. Blood 119(22):5211-5214.
60. Guy CS, et al. (2013) Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat Immunol 14(3):262-270.
61. Fortini ME, Bilder D (2009) Endocytic regulation of Notch signaling. Curr Opin Genet Dev 19(4): 323-328.
62. Zhao B, et al. (2011) Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci USA 108(36):14902-14907.
63. Zhang X, et al. (2016) Identification of focally amplified lineage-specific superenhancers in human epithelial cancers. Nat Genet 48(2):176-182.
64. Shi J, et al. (2013) Role of SWI/SNF in acute leukemia maintenance and enhancermediated Myc regulation. Genes Dev 27(24):2648-2662.
65. Rossi D, et al. (2013) Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 121(8):1403-1412.
66. Wu Y, et al. (2010) Therapeutic antibody targeting of individual Notch receptors. Nature 464(7291):1052-1057.
67. Bereshchenko OR, Gu W, Dalla-Favera R (2002) Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 32(4):606-613.
68. Pasqualucci L, Kitaura Y, Gu H, Dalla-Favera R (2006) PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells. Proc Natl Acad Sci USA 103(2):395-400.
69. Dominguez-Sola D, et al. (2012) The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol 13(11):1083-1091.
70. Wang H, et al. (2011) Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells. Proc Natl Acad Sci USA 108(36):14908-14913.
71. Blecher-Gonen R, et al. (2013) High-throughput chromatin immunoprecipitation for genome-wide mapping of in vivo protein-DNA interactions and epigenomic states. Nat Protoc 8(3):539-554.
72. Langmead B, Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. Nat Methods 9(4):357-359.
73. Li H, et al.; 1000 Genome Project Data Processing Subgroup (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25(16):2078-2079.
74. Giannopoulou EG, Elemento O (2011) An integrated ChIP-seq analysis platform with customizable workflows. BMC Bioinformatics 12:277.
75. Song Q, Smith AD (2011) Identifying dispersed epigenomic domains from ChIP-Seq data. Bioinformatics 27(6):870-871.
76. Hallek M, et al.; International Workshop on Chronic Lymphocytic Leukemia (2008)Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446-5456.
77. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402-408.
78. Trapnell C, Pachter L, Salzberg SL (2009) TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics 25(9):1105-1111.
79. Trapnell C, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28(5):511-515.
80. Benjamini YH (1995) Controlling the false discovery rate-A practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57:289-300.
81. Basso K, Dalla-Favera R (2015) Germinal centres and B cell lymphomagenesis. Nat Rev Immunol 15(3):172-184.
82. Victora GD, et al. (2012) Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood 120(11):2240-2248.
83. Palomero T, et al. (2006) CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors. Leukemia 20(7):1279-1287.
84. Khan A, Zhang X (2016) dbSUPER: A database of super-enhancers in mouse and human genome. Nucleic Acids Res 44(D1):D164-D171.